GHRL and metabolic dysfunction-associated steatotic liver disease: Mao et al. [108] observed the therapeutic effect of ghrelin on nonalcoholic fatty liver disease (NAFLD) and found that subcutaneous ghrelin administration reduces TG content in the HFD group in vivo and in the FFA group in vitro.